Diadema Partners LP Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Diadema Partners LP purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,767 shares of the company's stock, valued at approximately $999,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. raised its stake in shares of BioNTech by 7.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after buying an additional 128 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after acquiring an additional 150 shares during the period. Midwest Professional Planners LTD. raised its position in BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after acquiring an additional 222 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in BioNTech by 3.9% in the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock valued at $666,000 after acquiring an additional 224 shares during the period. Finally, Atomi Financial Group Inc. boosted its position in shares of BioNTech by 6.7% during the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock worth $414,000 after purchasing an additional 229 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analysts Set New Price Targets

BNTX has been the subject of several recent analyst reports. Morgan Stanley reduced their price objective on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. HC Wainwright reduced their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup started coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 target price for the company. Finally, BMO Capital Markets lifted their price objective on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $143.44.

BioNTech Stock Down 15.4 %

NASDAQ:BNTX traded down $18.52 on Friday, hitting $102.02. 6,438,309 shares of the company's stock traded hands, compared to its average volume of 897,110. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $24.48 billion, a PE ratio of -48.58 and a beta of 1.07. The firm has a 50-day moving average price of $101.72 and a 200-day moving average price of $110.64. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.90 earnings per share. Equities analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.